Floatz logo

231 assets in Endometrial Carcinoma

Therapeutic assets addressing Endometrial Carcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

AssetSponsorPhaseRating
Tislelizumab
Endometrial Carcinoma
HutchmedP1/2CC (46)
Pyruvate
Endometrial Carcinoma
Chang Gung Memorial HospitalP2CC (45)
Afuresertib
Endometrial Carcinoma
Laekna LimitedP1/2CC (44)
Bemarituzumab
Endometrial Carcinoma
Centre Leon BerardP1/2CC (44)
Bbi-355
Endometrial Carcinoma
Boundless Bio, Inc.P1CC (43)
Bbi-825
Endometrial Carcinoma
Boundless Bio, Inc.P1CC (43)
Bet Bromodomain Inhibitor Zen-3694
Endometrial Carcinoma
National Cancer Institute (NCI)P1CC (43)
Cabozantinib
Endometrial Carcinoma
M.D. Anderson Cancer CenterP1CC (43)
Cetuximab
Endometrial Carcinoma
Fate TherapeuticsP1CC (43)
Cobimetinib
Endometrial Carcinoma
National Cancer Institute (NCI)P1CC (43)
Elimusertib
Endometrial Carcinoma
National Cancer Institute (NCI)P1CC (43)
Erx-315
Endometrial Carcinoma
EtiraRx Australia Pty LtdP1CC (43)
ft836
Endometrial Carcinoma
Fate TherapeuticsP1CC (43)
Futibatinib
Endometrial Carcinoma
Boundless Bio, Inc.P1CC (43)
Ipn 60090
Endometrial Carcinoma
M.D. Anderson Cancer CenterP1CC (43)
nkt3964
Endometrial Carcinoma
NiKang Therapeutics, Inc.P1CC (43)
Opb-201
Endometrial Carcinoma
Outpace Bio, Inc.P1CC (43)
Pelcitoclax
Endometrial Carcinoma
National Cancer Institute (NCI)P1CC (43)
Talazoparib
Endometrial Carcinoma
M.D. Anderson Cancer CenterP1CC (43)
Tuvusertib
Endometrial Carcinoma
National Cancer Institute (NCI)P1CC (43)
Veliparib
Endometrial Carcinoma
National Cancer Institute (NCI)P1CC (43)
Vudalimab
Endometrial Carcinoma
Xencor, Inc.P2CC (42)
177lu-betabart
Endometrial Carcinoma
Radiopharm Theranostics, LtdP1/2CC (41)
Alnodesertib
Endometrial Carcinoma
Artios Pharma LtdP1/2CC (41)
Amxt1501
Endometrial Carcinoma
Aminex Therapeutics, Inc.P1/2CC (41)
Avzo-021
Endometrial Carcinoma
Avenzo Therapeutics, Inc.P1/2CC (41)
Benmelstobart
Endometrial Carcinoma
Beijing Tide Pharmaceutical Co., LtdP1/2CC (41)
Camizestrant
Endometrial Carcinoma
AstraZenecaP1/2CC (41)
Eflornithine
Endometrial Carcinoma
Aminex Therapeutics, Inc.P1/2CC (41)
eik1005
Endometrial Carcinoma
Eikon TherapeuticsP1/2CC (41)
Enzalutamide
Endometrial Carcinoma
Cancer Research UKP1/2CC (41)
Etx-19477
Endometrial Carcinoma
858 Therapeutics, Inc.P1/2CC (41)
Fianlimab
Endometrial Carcinoma
Regeneron PharmaceuticalsP1/2CC (41)
Fruquintinib
Endometrial Carcinoma
HutchmedP1/2CC (41)
Gamma1 Heavy Chain Humanized (1-450) [Vh (Homo Sapiens Ighv4-31*01 (89.9%) -(Ighd) -Ighj4*01 (92.9%), Cdr-Imgt [9.7.13] (26-34.52-58.97-109)) (1-120) -Homo Sapiens Ighg1*01 (100%), G1M17,1 Ch1 K120, D12, L14 (Ch1 K120 (217) (121-218), Hinge 1-15 (219-233), Ch2 (234-343), Ch3 D12 (359), L14 (361) (344-448), Chs (449-450)) (121-450)], (223-214')-Disulfide With Kappa Light Chain Humanized (1'-214') [V-Kappa (Homo Sapiens Igkv1-12*01 (85.3%)-Igkj2*01 (100%), Cdr-Imgt [6.3.9] (27-32.50-52.89-97)) (1'-107') -Homo Sapiens Igkc*01 (100%), Km3 A45.1 (153), V101 (191) (108'-214')]; Dimer (229-229'':232-232'')-Bisdisulfide, Produced In Chinese Hamster Ovary (Cho) Cells, Derived From The Cell Line Cho-K1,Glycoform Alfa
Endometrial Carcinoma
Cancer Research UKP1/2CC (41)
gen1107
Endometrial Carcinoma
GenmabP1/2CC (41)
gsk4418959
Endometrial Carcinoma
GlaxoSmithKlineP1/2CC (41)
ilb2109
Endometrial Carcinoma
Innolake BiopharmP1/2CC (41)
Immunoglobulin G1 [240-Alanine,241-Alanine], Anti-(Human Folate Receptor ?) (Human Monoclonal Pro1184 ?1-Chain, Complex With Human Monoclonal Pro1184 ?-Chain, Dimer, 214??,214???,226,226?,232,232?,235,235?-Octakis(Thioether) With N6-[39-[Bis(1-Deoxy-D-Glucitol-1-Yl)Amino]-1-Oxo-4,7,10,13,16,19,22,25,28,31,34,37-Dodecaoxanonatriacont-1-Yl]-N2-[6-(3-Mercapto-2,5-Dioxo-1-Pyrrolidinyl)-1-Oxohexyl]-L-Lysyl-L-Valyl-N5-(Aminocarbonyl)-N-[4-[[[[[(1S,9S)-9-Ethyl-5-Fluoro-2,3,9,10,13,15-Hexahydro-9-Hydroxy-4-Methyl-10,13-Dioxo-1H,12H-Benzo[De]Pyrano[3?,4?:6,7]Indolizino[1,2-B]Quinolin-1-Yl]Amino]Carbonyl]Oxy]Methyl]Phenyl]-L-Ornithinamide
Endometrial Carcinoma
GenmabP1/2CC (41)
Immunoglobulin G4 [237-Proline,242-Proline,243-Valine,244-Alanine,De-245-Glycine], Anti-(Human Mucin-16) (Human Monoclonal Regn5668 ?4-Chain), Disulfide With Human Monoclonal Regn5668 ?-Chain, (235?228?),(238?231?)-Bis(Disulfide) With Immunoglobulin G4 [230-Proline,235-Proline,236-Valine,237-Alanine,De-238-Glycine,436-Arginine,437-Phenylalanine,446-Proline] Anti-(Human Cd28 Antigen) (Human Monoclonal Regn5668 ?4-Chain) Disulfide With Human Monoclonal Regn5668 ?-Chain
Endometrial Carcinoma
Regeneron PharmaceuticalsP1/2CC (41)
Immunoglobulin G4, Anti-(Human Programmed Cell Death Protein 1) (Human Monoclonal Regn2810 Heavy Chain), Disulfide With Human Monoclonal Regn2810 .Kappa.-Chain, Dimer
Endometrial Carcinoma
Regeneron PharmaceuticalsP1/2CC (41)
Inv-6452
Endometrial Carcinoma
Shenzhen Ionova Life Sciences Co., Ltd.P1/2CC (41)
Inv-8989
Endometrial Carcinoma
Shenzhen Ionova Life Sciences Co., Ltd.P1/2CC (41)
mdx2001
Endometrial Carcinoma
ModeX Therapeutics, An OPKO Health CompanyP1/2CC (41)
mt-4561
Endometrial Carcinoma
Tanabe Pharma America, Inc.P1/2CC (41)
Neoantigen Specific Tcr-T Cell Drug Product
Endometrial Carcinoma
Alaunos TherapeuticsP1/2CC (41)
Palacaparib
Endometrial Carcinoma
AstraZenecaP1/2CC (41)
Pasifolate Exatecan
Endometrial Carcinoma
Elucida OncologyP1/2CC (41)
ql2107
Endometrial Carcinoma
Qilu Pharmaceutical Co., Ltd.P1/2CC (41)
qls5132
Endometrial Carcinoma
Qilu Pharmaceutical Co., Ltd.P1/2CC (41)
Showing 101 to 150 of 231 assets
PreviousPage 3 of 5Next